Safety and Efficacy of SUM-191 for Patients With Bacterial Conjunctivitis
Part of paid clinical trials in Austin, Texas.
- Sponsor
- Senju USA, Inc.
- Study ID
- NCT07565103
- Phase
- PHASE1/PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Bacterial Conjunctivitis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- SUM-191 — DRUGPart 1 (SAD): SUM-191 is administrated a single dose topically. Part 2 (MAD): SUM-191 is administrated TID topically for 6 days. Part 3: SUM-191 is administrated TID topically for 6 days.
- Placebo — DRUGPart 1 (SAD): Placebo is administrated a single dose topically. Part 2 (MAD): Placebo is administrated TID topically for 6 days. Part 3: Placebo is administrated TID topically for 6 days.
Study Details
This is a seamless Phase I/II, randomized, double-masked, placebo-controlled, multicenter trial to evaluate single and multiple-dose safety and tolerability of SUM-191 in healthy participants in Parts 1 (SAD) and 2 (MAD) ; and multiple-dose efficacy and safety of SUM-191 in participants with bacterial conjunctivitis in Part 3.
Key Dates
- Start date
- Jun 15, 2026
- Status verified
- Apr 2026
- Primary completion
- Aug 15, 2028
- Completion
- Aug 15, 2028
Study Design
- Enrollment
- 426 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: SUM-191Participants will receive SUM-191.
- Placebo Comparator: PlaceboParticipants will receive Placebo
Primary Outcome Measure
Incident of Adverse Events (AEs) (Part 1 and Part 2) [ Time Frame: Part 1: From Day 1 to Day 7 Part 2: From Day 1 to Day 14 ]
Central Contacts
- Mizue Takahara310-935-0505
- Satoshi Yamamoto310-935-0505
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Austin Clinical Research Unit | Austin | Texas | 78744 |
Find similar trials in Austin, TX
By research site
Related Studies
- Efficacy of Fusidic Acid 1% in the Treatment of Bacterial ConjunctivitisPHASE3 · Recruiting · Baxis Pharmaceuticals, Inc. · Little Rock, Arkansas